Comparisons between cancer cells carrying HRAS wildtype and those with oncogenic HRAS mutations have highlighted the vulnerability of oncogenic HRAS-driven cancer cells to genetic and pharmacological TRPML1 inhibition, indicating TRPML1 as a potential target for HRAS-driven cancers [21,30]. The gene discussed is HRAS; the disease is cancer.